CN1481251A - 治疗病毒感染的联合方法 - Google Patents

治疗病毒感染的联合方法 Download PDF

Info

Publication number
CN1481251A
CN1481251A CNA01820919XA CN01820919A CN1481251A CN 1481251 A CN1481251 A CN 1481251A CN A01820919X A CNA01820919X A CN A01820919XA CN 01820919 A CN01820919 A CN 01820919A CN 1481251 A CN1481251 A CN 1481251A
Authority
CN
China
Prior art keywords
hiv
polypeptide
pharmaceutically acceptable
perhaps
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA01820919XA
Other languages
English (en)
Chinese (zh)
Inventor
B��M����³��
B·M·巴鲁迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1481251A publication Critical patent/CN1481251A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Peptides Or Proteins (AREA)
CNA01820919XA 2000-12-19 2001-12-17 治疗病毒感染的联合方法 Pending CN1481251A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25665700P 2000-12-19 2000-12-19
US60/256,657 2000-12-19

Publications (1)

Publication Number Publication Date
CN1481251A true CN1481251A (zh) 2004-03-10

Family

ID=22973061

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA01820919XA Pending CN1481251A (zh) 2000-12-19 2001-12-17 治疗病毒感染的联合方法

Country Status (12)

Country Link
US (1) US20050065319A1 (https=)
EP (1) EP1385534A2 (https=)
JP (1) JP2005500981A (https=)
CN (1) CN1481251A (https=)
AR (1) AR031931A1 (https=)
BR (1) BR0116253A (https=)
CA (1) CA2431919A1 (https=)
HU (1) HUP0302241A3 (https=)
MX (1) MXPA03005526A (https=)
NO (1) NO20032769L (https=)
WO (1) WO2002056902A2 (https=)
ZA (1) ZA200304560B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013127299A1 (zh) * 2012-02-28 2013-09-06 中国人民解放军军事医学科学院毒物药物研究所 用于抑制hiv的多肽及其作用靶点

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2400553A (en) * 2003-04-14 2004-10-20 Cipla Ltd Antiviral pharmaceutical combination of lamivudine, stavudine and efavirenz, or derivatives thereof
AU2004251228B2 (en) * 2003-05-16 2008-04-24 University Of Maryland Biotechnology Institute Compositions for down-regulation of CCR5 expression and methods of use therefor
JP2008520684A (ja) 2004-11-17 2008-06-19 アブジェニックス・インコーポレーテッド Ｉｌ−１３に対する完全ヒトモノクローナル抗体
US20070123538A1 (en) * 2005-11-30 2007-05-31 Schering Corporation Compositions comprising a combination of CCR5 and CXCR4 antagonists
US20100152301A1 (en) * 2005-12-01 2010-06-17 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Treatment of Viral Infections
EP1886696A1 (en) * 2006-08-03 2008-02-13 Endotis Pharma Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
AU723537B2 (en) * 1995-06-07 2000-08-31 Trimeris Inc. The treatment of HIV and other viral infections using combinatorial therapy
US6281331B1 (en) * 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
US6391865B1 (en) * 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
US6387930B1 (en) * 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
CN1349408A (zh) * 1999-05-04 2002-05-15 先灵公司 聚乙二醇化干扰素α－CCR5拮抗剂联合HIV疗法
HK1039330B (en) * 1999-05-04 2005-12-09 Schering Corporation Piperidine derivatives useful as ccr5 antagonists
US6689765B2 (en) * 1999-05-04 2004-02-10 Schering Corporation Piperazine derivatives useful as CCR5 antagonists

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013127299A1 (zh) * 2012-02-28 2013-09-06 中国人民解放军军事医学科学院毒物药物研究所 用于抑制hiv的多肽及其作用靶点
CN104039815A (zh) * 2012-02-28 2014-09-10 中国人民解放军军事医学科学院毒物药物研究所 用于抑制hiv的多肽及其作用靶点

Also Published As

Publication number Publication date
EP1385534A2 (en) 2004-02-04
MXPA03005526A (es) 2003-10-06
US20050065319A1 (en) 2005-03-24
CA2431919A1 (en) 2002-07-25
JP2005500981A (ja) 2005-01-13
HUP0302241A2 (hu) 2003-11-28
BR0116253A (pt) 2006-05-02
WO2002056902A3 (en) 2002-12-05
NO20032769L (no) 2003-08-18
HUP0302241A3 (en) 2005-06-28
WO2002056902A2 (en) 2002-07-25
NO20032769D0 (no) 2003-06-18
ZA200304560B (en) 2005-07-27
AR031931A1 (es) 2003-10-08

Similar Documents

Publication Publication Date Title
ES2238277T3 (es) Terapia anti-vih con una combinacion de un interferon alfa-pegilado y un antagonista de ccr5.
ZA200307474B (en) CCR5 antagonists useful for treating AIDS.
US6635646B1 (en) Pegylated interferon alfa-CCR5 antagonist combination HIV therapy
CN1481251A (zh) 治疗病毒感染的联合方法
CN1100564C (zh) 用于治疗hiv感染的药物、其组合物及其用途
MXPA02008756A (es) Terapia adyuvante inmune de virus de inmunodeficiencia humana.
US20070123538A1 (en) Compositions comprising a combination of CCR5 and CXCR4 antagonists
JP2005500981A5 (https=)
EP1034790A2 (en) HIV therapy
AU2002245148A1 (en) CCR5 antagonist and DP-178 polypeptide for treating viral infections
US20020182179A1 (en) HIV Therapy
HK1027286A (en) Hiv therapy
MX2008007042A (en) Compositions comprising a combination of ccr5 and cxcr4 antagonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication